Shannon I L, Trodahl J N, Starcke E N
Cancer. 1978 May;41(5):1746-50. doi: 10.1002/1097-0142(197805)41:5<1746::aid-cncr2820410515>3.0.co;2-c.
A saliva substitute, VA-OraLube, was evaluated for ability to reharden dental enamel and to relieve intraoral soft tissue symptoms in patients receiving radiotherapy for malignancies of the head and neck. Treatments of 15, 30 and 60 minutes rehardened enamel by 3.1%, 4.0%, and 5.5%, respectively. In the second experiment, treatment for 60 minutes with the complete solution rehardened enamel by 5.2%. Omitting calcium, phosphorus and/or fluoride from the formulation greatly decreased this rehardening potential. Treatment of enamel with fresh whole saliva induced rehardening at a 7.3% level in comparison to the 5.5% and 5.2% derived by using the saliva substitute. Since the xerostomic patient usually uses the product very frequently, there is a remineralization potential of significant consequence. A total of 125 xerostomic patients used the saliva substitute on an ad lib basis over a period of 4 months. Patient responses indicated a very high level of acceptance and the virtual elimination of troublesome problems previously associated with the dry mouth state.
一种唾液替代品VA-OraLube,被评估用于对头颈部恶性肿瘤接受放疗的患者重新硬化牙釉质以及缓解口腔软组织症状的能力。15分钟、30分钟和60分钟的治疗分别使牙釉质再矿化3.1%、4.0%和5.5%。在第二个实验中,用完整溶液治疗60分钟使牙釉质再矿化5.2%。配方中省略钙、磷和/或氟会大大降低这种再矿化潜力。用新鲜全唾液处理牙釉质可使再矿化率达到7.3%,相比之下,使用唾液替代品的再矿化率为5.5%和5.2%。由于口干燥症患者通常非常频繁地使用该产品,因此存在显著的再矿化潜力。共有125名头颈部恶性肿瘤放疗后口干燥症患者在4个月的时间里随意使用了这种唾液替代品。患者反馈表明该产品的接受度非常高,并且几乎消除了之前与口干状态相关的麻烦问题。